Zaleplon and Driving Impairment

    Volume 48, Issue 3 (May 2003)

    ISSN: 0022-1198


    Published Online: 1 May 2003

    Page Count: 3

    (Received 5 October 2002; accepted 3 December 2002)


    Zaleplon, a sedative-hypnotic, was identified in the blood of a subject arrested for impaired driving. Symptoms reported were those of central nervous system (CNS) depression. The zaleplon concentration was determined to be 0.13 µg/mL. Symptoms included slow movements and reactions, poor coordination, and lack of balance. Although no quantitative relationship between blood concentrations and degree of driving impairment is currently possible, it is reasonable to conclude that because of its specific activity as a sedative-hypnotic, blood concentrations consistent with doses exceeding therapeutic concentrations of zaleplon have the potential to cause impairment of psychomotor function, and would impair a person's level of consciousness and driving ability.

    Paper ID: JFS2002357

    DOI: 10.1520/JFS2002357

    ASTM International
    is a member of CrossRef.

    Title Zaleplon and Driving Impairment
    Symposium , 0000-00-00
    Committee E30